{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-105634","form_type":"8-K","ticker":"TOVX","cik":"0000894158","company_name":"Theriva Biologics, Inc.","filed_at":"2024-10-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.293532+00:00","generated_at":"2026-05-30T21:56:08.722157+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Theriva Biologics DSMC recommends advancing SYN-004 trial to Cohort 3 after positive Cohort 2 safety data","bullets":["DSMC reviewed safety and PK data from Cohort 2 (19 patients) and recommended study proceed to Cohort 3 using cefepime.","No SAEs or AEs determined related to study drug; 15 SAEs reported among 10 patients typical for allo-HCT.","No patient blood samples positive for SYN-004 at any timepoint; piperacillin PK as expected.","Company pursuing additional funding to enable Cohort 3 conduct; Phase 1b/2a trial remains blinded."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-105634","json":"https://secwatch.observer/filing/0001104659-24-105634.json","markdown":"https://secwatch.observer/filing/0001104659-24-105634.md","text":"https://secwatch.observer/filing/0001104659-24-105634.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/894158/000110465924105634/0001104659-24-105634-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894158/000110465924105634/tm2425487d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T21:56:08.722157+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}